Schrödinger to offer Eli Lilly's AI drug discovery platform with its own software

January 9 (Reuters) – Schrödinger (SDGR.O)opens a new tab On Friday, it announced a partnership with Eli Lilly (LLY.N).opens a new tab The pharmaceutical giant will offer its AI-based platform, TuneLab, on its drug discovery software.

Integrating Lilly's TuneLab with Schrödinger's Live Design will give biotech companies direct access to an artificial intelligence platform, helping speed drug development, the biotech software maker said.

LiveDesign, Schrödinger's cloud-based platform, helps chemists design compounds and predict properties such as absorption and distribution of experimental drugs, helping them understand how drugs work in the body.

Drug developers are increasingly employing AI in discovery and safety testing for faster and cheaper results, in line with the FDA's push to reduce animal testing in the near future.

Karen Akinsanya, Schrödinger's chief strategy officer, said TuneLab will be available to current LiveDesign customers in the first quarter of this year, but the AI software will be available to new users by the second quarter.

Lilly launched TuneLab, an AI and machine learning platform, last year to give biotech companies access to drug discovery models trained on years of research data. The drug company has already announced partnerships with several biotech companies to use its platform for drug development.

“More biotechs using models means more diverse training data… ultimately moving molecules to discovery faster for waiting patients,” said Aliza Apple, global head of Lilly Tune Labs.

Report by Sneha SK in Bangalore. Editing: Leroy Leo

Our standards: Thomson Reuters Trust Principles.opens a new tab

Source link